1. Scrip
  2. >>R&D

GSK Counters Innoviva’s Gonorrhea Hit

 
• By Elizabeth Cairns

Both groups have posted hits with similar novel antibiotics, and both have a lot riding on commercial success.  

LONDON- JUNE, 2018: The GlaxoSmithKline headquarters building in Brentford, west London. A British global pharmaceuticals company.

Innoviva, Inc.’s antibiotic zoliflodacin hit – just – in a Phase III gonorrhea trial late last year. Now GSK plc has reported a success with its potential rival gepotidacin, and both have a chance of becoming the first new antibiotics for the infection to gain approval for some years.

Key Takeaways
  • GSK’s gepotidacin has hit in a Phase III gonorrhea trial
  • Innoviva’s similarly acting zoliflodacin did the same in November
  • Full data on both could have major commercial

But in neither case has much detail been revealed, and full data could change the picture markedly

More from Clinical Trials

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from R&D

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.